Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Lee Herring, from Pembroke in South Wales, didn't resort to a weight loss jab, saying it was 'so worth it'. The receptionist, ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

While still early, the data suggests a stronger weight-reducing effect than Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide ... but had also not reached a plateau. Lilly is losing no time ...

To tackle the existing energy crisis, the European Union said on Monday that it is exploring the potential for small hydropower generation in partnership with the Plateau State government. This ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...